Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) EBIT: 2009-2024

Historic EBIT for RedHill Biopharma (RDHL) over the last 16 years, with Dec 2024 value amounting to -$14.6 million.

  • RedHill Biopharma's EBIT rose 226.72% to $53.8 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$44.0 million, marking a year-over-year increase of 70.69%. This contributed to the annual value of -$14.6 million for FY2024, which is 215.68% down from last year.
  • As of FY2024, RedHill Biopharma's EBIT stood at -$14.6 million, which was down 215.68% from $12.6 million recorded in FY2023.
  • In the past 5 years, RedHill Biopharma's EBIT registered a high of $63.7 million during FY2020, and its lowest value of -$81.1 million during FY2021.
  • For the 3-year period, RedHill Biopharma's EBIT averaged around -$14.9 million, with its median value being -$14.6 million (2024).
  • Its EBIT has fluctuated over the past 5 years, first slumped by 227.40% in 2021, then surged by 129.48% in 2023.
  • Yearly analysis of 5 years shows RedHill Biopharma's EBIT stood at $63.7 million in 2020, then tumbled by 227.40% to -$81.1 million in 2021, then surged by 47.19% to -$42.8 million in 2022, then soared by 129.48% to $12.6 million in 2023, then tumbled by 215.68% to -$14.6 million in 2024.